160 related articles for article (PubMed ID: 37702177)
21. The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal Products.
Palomo GM; Pose-Boirazian T; Naumann-Winter F; Costa E; Duarte DM; Kalland ME; Malikova E; Matusevicius D; Vitezic D; Larsson K; Magrelli A; Stoyanova-Beninska V; Mariz S
Mol Ther; 2023 Dec; 31(12):3414-3423. PubMed ID: 37794679
[TBL] [Abstract][Full Text] [Related]
22. Requirements for Clinical Trials with Gene Therapy and Transplant Products in Switzerland.
Marti A
Adv Exp Med Biol; 2015; 871():131-45. PubMed ID: 26374216
[TBL] [Abstract][Full Text] [Related]
23. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU.
Joppi R; Bertele' V; Garattini S
Eur J Clin Pharmacol; 2013 Apr; 69(4):1009-24. PubMed ID: 23090701
[TBL] [Abstract][Full Text] [Related]
24. Development and regulation of biosimilars: current status and future challenges.
Tsiftsoglou AS; Ruiz S; Schneider CK
BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
[TBL] [Abstract][Full Text] [Related]
25. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.
Winstone J; Chadda S; Ralston S; Sajosi P
Orphanet J Rare Dis; 2015 Oct; 10():139. PubMed ID: 26511061
[TBL] [Abstract][Full Text] [Related]
26. Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective.
Tomeo F; Mariz S; Brunetta AL; Stoyanova-Beninska V; Penttila K; Magrelli A
Br J Clin Pharmacol; 2021 Nov; 87(11):4183-4196. PubMed ID: 33772837
[TBL] [Abstract][Full Text] [Related]
27. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
28. Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU.
Vokinger KN; Kesselheim AS
BMJ Open; 2019 Oct; 9(10):e028634. PubMed ID: 31601584
[TBL] [Abstract][Full Text] [Related]
29. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
Kroes BH
J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
[TBL] [Abstract][Full Text] [Related]
30. Traits, trends and hits of orphan drug designations in cystic fibrosis.
Costa E; Girotti S; van den Ham HA; Cipolli M; van der Ent CK; Taylor-Cousar JL; Leufkens HGM
J Cyst Fibros; 2023 Sep; 22(5):949-957. PubMed ID: 37507282
[TBL] [Abstract][Full Text] [Related]
31. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
32. Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
Rivera VM
Neurol Ther; 2019 Dec; 8(2):177-184. PubMed ID: 31313222
[TBL] [Abstract][Full Text] [Related]
33. Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review.
Goring S; Taylor A; Müller K; Li TJJ; Korol EE; Levy AR; Freemantle N
BMJ Open; 2019 Feb; 9(2):e024895. PubMed ID: 30819708
[TBL] [Abstract][Full Text] [Related]
34. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe.
Schuessler-Lenz M; Herberts C; Reischl I; Ruiz S; Celis P; Beuneu C; Kjeken R; Timón M
Adv Exp Med Biol; 2023; 1430():1-21. PubMed ID: 37526839
[TBL] [Abstract][Full Text] [Related]
35. Patient-reported outcome claims in European and United States orphan drug approvals.
Jarosławski S; Auquier P; Borissov B; Dussart C; Toumi M
J Mark Access Health Policy; 2018; 6(1):1542920. PubMed ID: 30425804
[No Abstract] [Full Text] [Related]
36. Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non-orphan, Non-oncology Drugs in the European Union and United States from 2012-2016.
Morant AV; Jagalski V; Vestergaard HT
Clin Transl Sci; 2019 Jul; 12(4):361-370. PubMed ID: 30681284
[TBL] [Abstract][Full Text] [Related]
37. Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation.
Kalland ME; Pose-Boirazian T; Palomo GM; Naumann-Winter F; Costa E; Matusevicius D; Duarte DM; Malikova E; Vitezic D; Larsson K; Magrelli A; Stoyanova-Beninska V; Mariz S
Gene Ther; 2024 Mar; ():. PubMed ID: 38480914
[TBL] [Abstract][Full Text] [Related]
38. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
Pariser AR; Xu K; Milto J; Coté TR
Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
[TBL] [Abstract][Full Text] [Related]
39. Regulatory Aspects for Approval of Advanced Therapy Medicinal Products in the EU.
Fürst-Ladani S; Bührer A; Fürst W; Schober-Ladani N
Handb Exp Pharmacol; 2024; 284():367-387. PubMed ID: 37017789
[TBL] [Abstract][Full Text] [Related]
40. Bleomycin--electrical pulse delivery: electroporation therapy-bleomycin--Genetronics; MedPulser-bleomycin--Genetronics.
Drugs R D; 2004; 5(5):293-6. PubMed ID: 15357628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
